跳至主要内容
临床试验/NCT00647023
NCT00647023终止不适用

Incretin Secretion in Women With Polycystic Ovary Syndrome (PCOS)

Hvidovre University Hospital0 个研究点目标入组 66 人开始时间: 2004年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
终止
入组人数
66

研究概览

简要总结

The incretin hormones are secreted from the gastrointestinal tract in response to nutrient ingestion, and are responsible for 70 % of insulin secretion in response to glucose. The incretin response is attenuated in subjects with type 2 diabetes and other conditions associated with insulin resistance. Polycystic ovary syndrome (PCOS) is characterised by irregular periods and increased androgen levels. It is the most common endocrine disorder amongst young women at fertile age, and the most common cause of female infertility. Insulin resistance plays an important role in the development of the disease, and women with PCOS are at increased risk of developing tyoe 2 diabetes. the incretin hormones have not previously been investigated in women with PCOS, and the purpose of the present study was to investigate the secretion of the two most important incretin hormones Glucose-like peptide-1 (GLP-1) and Glucose dependent insulinotropic peptide (GIP) during a three hour oral glucose tolerance test.

研究设计

研究类型
Interventional
主要目的
Basic Science

入排标准

年龄范围
18 Years 至 38 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Subjects who fulfill the Rotterdam criteria for PCOS. Age 18-38

排除标准

  • Other endocrine diseases or diseases known to influence glucose/insulin/fat metabolism
  • Oral contraceptive administration within three months of study start

研究组 & 干预措施

A

Experimental

干预措施: metformin (Drug)

研究者

申办方类型
Other

相似试验

Incretin Secretion in Women With Polycystic Ovary... | 临床试验